Charles River Laboratories International (NYSE:CRL) PT Set at $315.00 by Stephens

Stephens set a $315.00 price target on Charles River Laboratories International (NYSE:CRLGet Rating) in a report issued on Monday, Stock Target Advisor reports.

A number of other analysts have also recently commented on the company. Jefferies Financial Group cut Charles River Laboratories International from a buy rating to a hold rating and cut their price objective for the company from $370.00 to $280.00 in a research report on Monday, April 25th. StockNews.com assumed coverage on Charles River Laboratories International in a research report on Thursday, March 31st. They set a hold rating for the company. Wells Fargo & Company dropped their price target on Charles River Laboratories International from $390.00 to $325.00 and set an overweight rating for the company in a research report on Monday, April 25th. Guggenheim assumed coverage on Charles River Laboratories International in a research report on Monday, May 23rd. They set a neutral rating for the company. They noted that the move was a valuation call. Finally, KeyCorp dropped their price target on Charles River Laboratories International from $390.00 to $300.00 in a research report on Thursday, May 5th. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of Moderate Buy and a consensus target price of $381.00.

Charles River Laboratories International stock opened at $220.58 on Monday. The stock has a market capitalization of $11.21 billion, a PE ratio of 26.87, a price-to-earnings-growth ratio of 1.28 and a beta of 1.27. Charles River Laboratories International has a 12 month low of $203.37 and a 12 month high of $460.21. The business has a 50 day simple moving average of $237.47 and a 200-day simple moving average of $290.16. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.34 and a quick ratio of 1.12.

Charles River Laboratories International (NYSE:CRLGet Rating) last posted its quarterly earnings data on Wednesday, May 4th. The medical research company reported $2.75 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.04. The business had revenue of $913.93 million during the quarter, compared to analysts’ expectations of $908.64 million. Charles River Laboratories International had a return on equity of 21.90% and a net margin of 11.64%. The business’s revenue was up 10.8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.53 earnings per share. On average, equities research analysts anticipate that Charles River Laboratories International will post 11.6 EPS for the current fiscal year.

In other news, Director George Massaro sold 178 shares of the company’s stock in a transaction on Monday, May 9th. The stock was sold at an average price of $230.96, for a total value of $41,110.88. Following the transaction, the director now owns 4,677 shares of the company’s stock, valued at approximately $1,080,199.92. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.10% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Mackenzie Financial Corp lifted its stake in Charles River Laboratories International by 182.5% during the 1st quarter. Mackenzie Financial Corp now owns 856,214 shares of the medical research company’s stock worth $243,139,000 after acquiring an additional 553,121 shares in the last quarter. Norges Bank acquired a new position in Charles River Laboratories International during the 4th quarter worth about $191,481,000. Clearbridge Investments LLC lifted its stake in Charles River Laboratories International by 28.2% during the 1st quarter. Clearbridge Investments LLC now owns 1,368,943 shares of the medical research company’s stock worth $388,739,000 after acquiring an additional 301,159 shares in the last quarter. First Republic Investment Management Inc. lifted its stake in Charles River Laboratories International by 3,792.3% during the 1st quarter. First Republic Investment Management Inc. now owns 156,277 shares of the medical research company’s stock worth $44,378,000 after acquiring an additional 152,262 shares in the last quarter. Finally, Marshall Wace LLP lifted its stake in Charles River Laboratories International by 50.3% during the 4th quarter. Marshall Wace LLP now owns 454,795 shares of the medical research company’s stock worth $171,358,000 after acquiring an additional 152,258 shares in the last quarter. 93.06% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile (Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Featured Stories

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.